Progesterone in Phase III trials
There continues to be a search for the drug which can address the complex neurological events which occur after brain injury. Progesterone, a female hormone, holds out promise in the search. Now in Phase III trials in to studies: Protect III and SyNAPSE, Progesterone may soon enter into use immediately following a brain injury to reduce the neurotoxic effects which occur at the cellular level and prevent the death of brain cells which continue past the original injury. Don Stein, PhD, at Emory University leads the research into Progesterone and his research work is receiving the wide recognition it deserves.
Click here to read an article about progesterone and brain injury.